EUVIMEDEUVIMED entdecken
Crossref

Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice

Xiujie Liu, Hongxia Sun, Qiannian Han, Zekai Wang, Jingjing Zeng, Jianwei Liu, Shining Ou, Keke Jin, Yuanyuan Shao, Dongbing Li, Zhuowei Gao, Fangyan Wang

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xiujie Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China; N…. Hauptthemen laut MEDLINE: Metformin, Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Zhejiang Province Public Welfare Technology Application Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD), a prevalent chronic liver disease, poses a substantial global health burden. Metformin is known for its protective effects in NAFLD, but the role of gut microbiota in the underlying mechanisms remains unclear. In this study, metformin was found to mitigate methionine-choline deficient (MCD) -diet induced NAFLD through reshaping the gut microbiota to increase ursodeoxycholic acid (UDCA) level, thereby inhibiting farnesoid X receptor (FXR) accompanied with activated autophagy. Specifically, using dirty cage experiments and 16S rRNA sequencing, it identified that metformin could reshape microbiota to release liver injury as confirmed by the results of histopathology and biochemical index detection. Furthermore, the bile acids were found to be altered by metformin, in which, the UDCA, a FXR natural inhibitor, was observed a significantly increase. Meanwhile, the inhibited FXR and activated autophagy in metformin-treated mice were captured using western blot, qRT-PCR and immunofluorescence analysis. In addition, the benefit of UDCA against NAFLD was demonstrated in UDCA treated mice. Further investigation with FXR siRNA introduced to HepG2 cells revealed that inhibiting FXR can reduce oleic acids induced cell injury with the autophagy activation. In conclusion, this study highlights metformin's potential to ameliorate NAFLD by reshaping gut microbiota, thereby upregulating UDCA in the liver and restoring cholesterol synthesis capacity, possibly via inhibiting FXR to activate autophagy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminNon-alcoholic Fatty Liver DiseaseGastrointestinal MicrobiomeReceptors, Cytoplasmic and NuclearUrsodeoxycholic AcidAnimalsAutophagyHumansMiceMaleHep G2 CellsMice, Inbred C57BLMethionineLiverCholine DeficiencyDisease Models, AnimalReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

AutophagyFXRGut microbiotaMetforminNAFLDUDCA

Substanzen

MetforminReceptors, Cytoplasmic and NuclearUrsodeoxycholic AcidMethionineReceptor, Farnesoid X-Activated

Autor:innen und Institutionen

  • Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China; Nottingham Ningbo China Beacons of Excellence Research and Innovation I…
  • Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China. Electronic address: jinkeke@wmu.edu.cn.
  • Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo 315048, Zhejiang, China.
  • Oncology Department, Shunde Hospital of Guangzhou University of Chinese Medicine, Guangdong 528300, China; Research Center of Translational Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Guangdon…
  • Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China. Electronic address: fangyan_wang@wmu.edu.cn.

Förderung

  • Zhejiang Province Public Welfare Technology Application Research Project

Zitieren

APA

Liu, X., Sun, H., Han, Q., Wang, Z., Zeng, J., Liu, J., Ou, S., Jin, K., Shao, Y., Li, D., Gao, Z., & Wang, F. (2025). Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114471

Vancouver

Liu X, Sun H, Han Q, Wang Z, Zeng J, Liu J, et al. Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114471

BibTeX
@article{Liu2025,
  author = {Liu, Xiujie and Sun, Hongxia and Han, Qiannian and Wang, Zekai and Zeng, Jingjing and Liu, Jianwei and Ou, Shining and Jin, Keke and Shao, Yuanyuan and Li, Dongbing and Gao, Zhuowei and Wang, Fangyan},
  title = {Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114471}
}
Kostenlos starten →